Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
NCT ID: NCT07306624
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
62 participants
INTERVENTIONAL
2026-01-10
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nelmastobart 800mg+Docetaxel 75mg/m2
Nelmastobart 800mg+Docetaxel 75mg/m2 fixed
Nelmastobart and Docetaxel
Nelmastobart 800mg and Docetaxel 75mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nelmastobart and Docetaxel
Nelmastobart 800mg and Docetaxel 75mg/m2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BTN1A1 TPS score 50
* Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
* Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or platinum-based chemotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 1.
* Adequate organ function as described in the protocol
* Adequate cardiac function as described in the protocol
* For female or male patients with reproductive potential: Agree to use contraception throughout the study and at least 5 months after the last dose.
* Life expectancy of at least 3 months
* Has agreed to provide archival tissue
Exclusion Criteria
* History of using Docetaxel for palliative therapy.
* Prior treatment with Cytotoxic chemotherapy or oral targeted therapy within 14 days.
* Investigational drugs within 5 half-lives.
* Monoclonal antibodies or ADCs within 4 weeks.
* Use or expected use of strong CYP3A4 inhibitors (e.g., ketoconazole) within 14 days prior to the first dose.
* Uncontrolled severe infection requiring IV treatment, or suspected infectious complications/fever.
* Requirement for continuous high-dose steroids (\>10 mg/day prednisone equivalent) or immunosuppressants within 7 days (excluding Docetaxel premedication; intermittent/replacement therapies allowed).
* Pregnant or breastfeeding women.
* History of autoimmune disease requiring systemic treatment within the last 2 years
* Known active symptomatic or radiologically unstable CNS lesions
* History of stroke, unstable angina, MI, or NYHA Class III-IV symptoms within 6 months, or current Class II.
* Systolic BP 160 mmHg or Diastolic BP 100 mmHg, or hypertensive encephalopathy.
* History of ILD, organizing/drug-induced pneumonia, or active pneumonia on screening (mild asymptomatic fibrosis requires consultation).
* Recipients of allogeneic stem cell or solid organ transplants.
* Vaccination with live or attenuated live vaccines within 30 days.
* Maligancies other than NSCLC
* Failure to recover from prior anti-cancer therapy side effects to CTCAE Grade 1
* Wide-field bone marrow radiation (\>30%) within 4 weeks, or limited palliative radiation within 2 weeks.
* Major surgery within 4 weeks or incomplete recovery from surgical side effects.
* Evidence of active HBV, HCV, or HIV infection (carriers with negative viral loads/RNA may be eligible).
* Clinically unstable pleural or peritoneal effusion (stable cases after intervention are allowed).
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
STCube, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea St. Vincent's Hospital
Gyeonggi-do, , South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Bundang Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STCUBE-004
Identifier Type: -
Identifier Source: org_study_id